Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. lessened its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 18.7% during the fourth quarter, HoldingsChannel reports. The fund owned 9,840 shares of the company’s stock after selling 2,260 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Apellis Pharmaceuticals were worth $589,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Whittier Trust Co. purchased a new stake in shares of Apellis Pharmaceuticals during the 4th quarter worth $221,000. Handelsinvest Investeringsforvaltning purchased a new stake in Apellis Pharmaceuticals during the fourth quarter worth about $245,000. Vanguard Group Inc. grew its position in Apellis Pharmaceuticals by 0.7% during the third quarter. Vanguard Group Inc. now owns 9,469,977 shares of the company’s stock worth $360,238,000 after buying an additional 68,687 shares during the period. Hudson Bay Capital Management LP purchased a new position in Apellis Pharmaceuticals in the third quarter valued at about $476,000. Finally, Polar Capital Holdings Plc lifted its position in shares of Apellis Pharmaceuticals by 126.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after acquiring an additional 588,875 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group upgraded Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the stock from $68.00 to $80.00 in a report on Monday, February 5th. Wedbush lowered their target price on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday, April 9th. UBS Group increased their price objective on shares of Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, Mizuho restated a “neutral” rating and set a $60.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.93.

Insiders Place Their Bets

In other news, Director A. Sinclair Dunlop sold 18,681 shares of the company’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $57.18, for a total transaction of $1,068,179.58. Following the completion of the transaction, the director now owns 173,998 shares of the company’s stock, valued at approximately $9,949,205.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 18,681 shares of Apellis Pharmaceuticals stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $57.18, for a total value of $1,068,179.58. Following the transaction, the director now owns 173,998 shares in the company, valued at approximately $9,949,205.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the sale, the insider now directly owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 406,651 shares of company stock valued at $25,130,257. Insiders own 7.50% of the company’s stock.

Apellis Pharmaceuticals Stock Down 1.1 %

Shares of NASDAQ APLS opened at $47.51 on Friday. The firm has a market cap of $5.73 billion, a P/E ratio of -10.60 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. Apellis Pharmaceuticals, Inc. has a 1 year low of $19.83 and a 1 year high of $94.75. The firm’s 50 day moving average price is $60.13 and its 200 day moving average price is $56.97.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.73). The business had revenue of $146.38 million for the quarter, compared to analysts’ expectations of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business’s revenue was up 545.9% on a year-over-year basis. During the same quarter last year, the firm earned ($1.50) earnings per share. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.33 earnings per share for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).